As in previous years, an article in the February issue of Nature Reviews Drug Discovery reports on the pharmaceuticals approved by the U.S. Food and Drug Administration in 2013 (Mullard, Nat Rev Drug Discov 2014; 13: 85-89; see also the respective report for 2012 in my post of February 28th, 2013).
Last Tuesday, on January 21st, 2014, the Swiss pharmaceutical company Roche published a press release on the first results of two Phase III studies with its glycine transporter inhibitor bitopertin (RG-1678) in patients with schizophrenia. Continue reading
In the June issue of Nature Reviews Drug Discovery Aaron Kesselheim and Jerry Avorn from Harvard Medical School in Boston, Massachusetts, published the results of their survey among physicians for the most transformative drugs of the past 25 years (Kesselheim und Avorn, Nat Rev Drug Discov 2013, 12: 425-431). Continue reading